CN1599619A - 治疗真皮损伤的方法和组合物 - Google Patents

治疗真皮损伤的方法和组合物 Download PDF

Info

Publication number
CN1599619A
CN1599619A CNA028244400A CN02824440A CN1599619A CN 1599619 A CN1599619 A CN 1599619A CN A028244400 A CNA028244400 A CN A028244400A CN 02824440 A CN02824440 A CN 02824440A CN 1599619 A CN1599619 A CN 1599619A
Authority
CN
China
Prior art keywords
itf
described method
compositions
trefoil
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028244400A
Other languages
English (en)
Chinese (zh)
Inventor
D·K·波多尔斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of CN1599619A publication Critical patent/CN1599619A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
CNA028244400A 2001-10-05 2002-10-07 治疗真皮损伤的方法和组合物 Pending CN1599619A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32767301P 2001-10-05 2001-10-05
US60/327,673 2001-10-05

Publications (1)

Publication Number Publication Date
CN1599619A true CN1599619A (zh) 2005-03-23

Family

ID=23277534

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028244400A Pending CN1599619A (zh) 2001-10-05 2002-10-07 治疗真皮损伤的方法和组合物

Country Status (8)

Country Link
US (1) US20030148949A1 (enExample)
EP (1) EP1438062A4 (enExample)
JP (1) JP2005508937A (enExample)
CN (1) CN1599619A (enExample)
AU (1) AU2002334886B2 (enExample)
CA (1) CA2462291A1 (enExample)
MX (1) MXPA04003267A (enExample)
WO (1) WO2003030824A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022105894A1 (zh) * 2020-11-20 2022-05-27 上海交通大学医学院附属瑞金医院 一种判断银屑病对il-17a抗体应答反应及其复发的标志物

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6525018B1 (en) 1999-05-17 2003-02-25 The General Hospital Corp. Treating eye disorders using intestinal trefoil proteins
US20030186882A1 (en) * 2001-07-31 2003-10-02 Podolsky Daniel K. Methods and compositions for treating and preventing distal bowel lesions
US20030185838A1 (en) * 2001-11-28 2003-10-02 Podolsky Daniel K. Methods and compositions for treating lesions of the respiratory epithelium
US20060189526A1 (en) * 2002-04-24 2006-08-24 Podolsky Daniel K Compositions containing an intestinal trefoil peptide and a mucoadhesive
US20040171544A1 (en) * 2001-04-24 2004-09-02 Barker Nicholas P. Trefoil domain-containing polypeptides and uses thereof
US7538082B2 (en) 2001-04-24 2009-05-26 The General Hospital Corporation Methods and compositions for treating oral and esophageal lesions
US20030105016A1 (en) * 2001-09-06 2003-06-05 Podolsky Daniel K. Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions
US20030181384A1 (en) * 2001-09-06 2003-09-25 Podolsky Daniel K. Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions
US20030185839A1 (en) * 2001-10-05 2003-10-02 Podolsky Daniel K. Methods and compositions for treating dermal lesions
AU2003224773B2 (en) * 2002-03-26 2010-08-26 The General Hospital Corporation Combination therapy using trefoil peptides
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US20060188471A1 (en) * 2002-10-31 2006-08-24 Podolsky Daniel K Methods of treating epithelial lesions
EP1587534A1 (en) * 2003-01-17 2005-10-26 Children's Hospital Medical Center Use of tff2, or agents inducing tff2, in the therapy of allergies
US20060057075A1 (en) * 2004-08-02 2006-03-16 Moshe Arkin Pharmaceutical and cosmeceutical wash-off mousse shampoo compositions, processes for preparing the same and uses thereof
US20060034779A1 (en) * 2004-08-02 2006-02-16 Agis Industries (1983) Ltd. Foamable compositions containing vitamin D3 analogues, processes for preparing same and methods of treatment utilizng same
US8075771B2 (en) * 2005-02-17 2011-12-13 E. I. Du Pont De Nemours And Company Apparatus for magnetic field gradient enhanced centrifugation
CA2609259A1 (en) * 2005-05-27 2006-12-07 Johnson & Johnson Consumer Companies, Inc. Discrete patch for viral lesions
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
RU2497679C2 (ru) 2008-10-02 2013-11-10 Милан Инк. Способ получения многослойного клеящегося ламинированного материала
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
EP2482788B1 (en) 2009-10-02 2022-12-14 Journey Medical Corporation Topical tetracycline compositions
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
WO2014042875A1 (en) * 2012-09-12 2014-03-20 Boston Scientific Scimed, Inc. Adhesive stent coating for anti-migration
US11793783B2 (en) 2015-08-05 2023-10-24 Cmpd Licensing, Llc Compositions and methods for treating an infection
US11446236B2 (en) 2015-08-05 2022-09-20 Cmpd Licensing, Llc Topical antimicrobial compositions and methods of formulating the same
US11684567B2 (en) 2015-08-05 2023-06-27 Cmpd Licensing, Llc Compositions and methods for treating an infection
US20200179409A1 (en) * 2015-08-05 2020-06-11 Cmpd Licensing, Llc Topical compositions and methods of formulating the same
CA2978573A1 (en) 2016-09-08 2018-03-08 Foamix Pharmaceuticals Ltd. Compositions and methods for treating rosacea and acne
PE20240888A1 (es) * 2020-12-08 2024-04-24 Imagine Pharma Llc Composiciones y metodos para tratar heridas

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4370317A (en) * 1980-09-10 1983-01-25 Novo Industri A/S Pancreatic spasmolytic polypeptide
US5843701A (en) * 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US6063755A (en) * 1991-02-14 2000-05-16 The General Hospital Corporation Intestinal trefoil proteins
US6221840B1 (en) * 1991-02-14 2001-04-24 The General Hospital Corporation Intestinal trefoil proteins
US5703047A (en) * 1992-09-21 1997-12-30 Board Of Regents, The University Of Texas System Methods and treatments for corneal healing with growth factors
DK6893D0 (da) * 1993-01-21 1993-01-21 Novo Nordisk As Peptid
US5563046A (en) * 1993-08-02 1996-10-08 Celtrix Pharmaceuticals, Inc. Fusion polypeptides and proteins
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
US6525018B1 (en) * 1999-05-17 2003-02-25 The General Hospital Corp. Treating eye disorders using intestinal trefoil proteins
US20030186882A1 (en) * 2001-07-31 2003-10-02 Podolsky Daniel K. Methods and compositions for treating and preventing distal bowel lesions
US6426404B1 (en) * 1997-08-25 2002-07-30 The General Hospital Corporation Receptor for intestinal trefoil factor
FR2769502B1 (fr) * 1997-10-14 2000-04-14 Sederma Sa Compositions a usage cosmetique ou dermopharmaceutique contenant un extrait vegetal obtenu a partir du trefle (trifolium sp.)
US6228840B1 (en) * 1998-02-27 2001-05-08 Edward T. Wei Melanocortin receptor antagonists and modulations of melanocortin receptor activity
CZ293735B6 (cs) * 1998-08-26 2004-07-14 Smithkline Beecham Corporation Farmaceutický prostředek pro léčbu plicní nemoci
US6372439B2 (en) * 1998-10-01 2002-04-16 James R. Goldenring Screen for gastric adenocarcinoma
US6685917B2 (en) * 2000-11-22 2004-02-03 Rxkinetix, Inc. Treatment of mucositis
JP2004515235A (ja) * 2000-12-08 2004-05-27 ノボ ノルディスク アクティーゼルスカブ Ｔｆｆペプチド
US20060189526A1 (en) * 2002-04-24 2006-08-24 Podolsky Daniel K Compositions containing an intestinal trefoil peptide and a mucoadhesive
US7538082B2 (en) * 2001-04-24 2009-05-26 The General Hospital Corporation Methods and compositions for treating oral and esophageal lesions
US20040171544A1 (en) * 2001-04-24 2004-09-02 Barker Nicholas P. Trefoil domain-containing polypeptides and uses thereof
MXPA03009772A (es) * 2001-04-24 2004-02-23 Gen Hospital Corp Metodos y composiciones para tratar lesiones orales y del esofago.
US20030105016A1 (en) * 2001-09-06 2003-06-05 Podolsky Daniel K. Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions
US20030153496A1 (en) * 2001-06-14 2003-08-14 Lars Thim Mucosal repair by TFF dimer peptides
AU2002315234A1 (en) * 2001-06-14 2003-01-02 Novo Nordisk A/S Mucosal repair by tff2 peptides
WO2003011117A2 (en) * 2001-07-31 2003-02-13 The General Hospital Corporation Methods and compositions for treating and preventing distal bowel lesions
US20030181384A1 (en) * 2001-09-06 2003-09-25 Podolsky Daniel K. Methods and compositions for treating vaginal, cervical, and uterine epithelial lesions
US20030185839A1 (en) * 2001-10-05 2003-10-02 Podolsky Daniel K. Methods and compositions for treating dermal lesions
EP1461076A4 (en) * 2001-11-28 2005-03-09 Gen Hospital Corp METHOD AND COMPOSITIONS FOR TREATING LESIONS OF THE RESPIRATORY EPITHEL
US20030215431A1 (en) * 2002-02-11 2003-11-20 Lars Thim Management of mucosal viscosity by TFF monomer peptides
AU2003224773B2 (en) * 2002-03-26 2010-08-26 The General Hospital Corporation Combination therapy using trefoil peptides
US20060188471A1 (en) * 2002-10-31 2006-08-24 Podolsky Daniel K Methods of treating epithelial lesions
US6984628B2 (en) * 2003-07-15 2006-01-10 Allergan, Inc. Ophthalmic compositions comprising trefoil factor family peptides
WO2005039619A1 (en) * 2003-10-03 2005-05-06 Allergan, Inc. Compositions and methods comprising prostaglandin-related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia
WO2005039640A1 (en) * 2003-10-03 2005-05-06 Allergan Inc. Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump inhibitor prodrugs
US7575920B2 (en) * 2005-07-25 2009-08-18 The Gi Company, Inc. Yeast expression vectors for production of ITF

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022105894A1 (zh) * 2020-11-20 2022-05-27 上海交通大学医学院附属瑞金医院 一种判断银屑病对il-17a抗体应答反应及其复发的标志物

Also Published As

Publication number Publication date
WO2003030824A3 (en) 2003-11-27
CA2462291A1 (en) 2003-04-17
JP2005508937A (ja) 2005-04-07
AU2002334886B2 (en) 2008-07-31
WO2003030824A2 (en) 2003-04-17
EP1438062A4 (en) 2005-06-01
MXPA04003267A (es) 2004-07-08
EP1438062A2 (en) 2004-07-21
US20030148949A1 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
CN1520309A (zh) 治疗口腔及食道损伤的方法和组合物
CA2462291A1 (en) Methods and compositions for treating dermal lesions
CN1617739A (zh) 用于治疗呼吸道上皮病变的方法和组合物
US20030078205A1 (en) Methods and compositions for treating and preventing distal bowel lesions
US20030185839A1 (en) Methods and compositions for treating dermal lesions
CN1655675A (zh) 利用三叶肽的联合治疗
CN1283997A (zh) 角质形成细胞生长因子－2制剂
AU2002334886A1 (en) Methods and compositions for treating dermal lesions
CN101031283A (zh) 用于递药的药用组合物和用其治疗或预防病症的方法
JP7576293B2 (ja) ファーバー病を治療するための組成物及び方法
US20030186882A1 (en) Methods and compositions for treating and preventing distal bowel lesions
CN1886138A (zh) 治疗青光眼的作为短形式c－maf转录因子拮抗剂的cdk2拮抗剂
WO2006056885A2 (en) Igf-1 isoforms
CN1541103A (zh) 诱导持续免疫应答的方法
HK1075204A (en) Methods and compositions for treating dermal lesions
US9101593B2 (en) Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
CA3088576C (en) COMPOSITION INTENDED FOR THE TREATMENT OF A PATIENT SUFFERING FROM ULCERATIVE COLITIS AND USE OF THE COMPOSITION AS A MEDICINE
HK1067049A (en) Methods and compositions for treating oral and esophageal lesions
Belik et al. Adiponectin gene expression in local fat depots in patients with coronary heart disease depending on the degree of coronary lesion
HK1076386A (en) Methods and compositions for treating lesions of the respiratory epithelium
CN1310679C (zh) 获得持续的转基因表达的方法
HK1081401A (en) Combination therapy using trefoil peptides
HK40088501A (zh) 用於治疗或预防纤维化、肥大或心力衰竭的髓源性生长因子
US6949512B1 (en) Therapeutic agent for the treatment of septicaemia its preparation and use
US20080051316A1 (en) Adrenomedullin and Adrenomedullin Binding Protein for Ischemia/Reperfusion Treatment

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1075204

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1075204

Country of ref document: HK